American Academy of Neurology Annual Meeting (AAN)

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed findings from the phase 3 CHAMPION-NMOSD trial of ravulizumab in patients with neuromyelitis optica spectrum disorder. [WATCH TIME: 5 minutes]

At the 2023 AAN Annual Meeting, the professor of neurology at the Geisel School of Medicine at Dartmouth talked about the effectiveness of a remote electrical neuromodulation device that offers potential relief for both episodic and chronic migraine. [WATCH TIME: 3 minutes]

Leo H. Wang, MD, PhD, FAAN, associate professor of neurology, University of Washington Medical Center, talked about the phase 2 study of losmapimod for facioscapulohumeral muscular dystrophy presented at the 2023 AAN Annual Meeting.

At the 2023 AAN Annual Meeting, the chief medical officer at Athira Pharma spoke about findings from a phase 2 trial in which various biomarkers related to neurodegeneration showed significant improvements. [WATCH TIME: 4 minutes]

The senior academic at the University of Sydney provided perspective on the promising findings of the phase 2 VISIONARY-MS study of CNM-Au8 in relapsing multiple sclerosis. [WATCH TIME: 6 minutes]

The professor of neurology at NYU Grossman School of Medicine and chief medical officer of the Epilepsy Foundation spoke about her talk on new treatments for drug resistant epilepsy given at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Jeffrey Bennett, MD, PhD, professor of neurology and ophthalmology at the University of Colorado Denver talked about inebilizumab for patients with NMOSD from the N-MOmentum trial.

The chief executive officer and president of Study Metrics Research provided commentary on a large-scale analysis further demonstrating efficacy and safety of zavegepant, regardless of aura status. [WATCH TIME: 3 minutes]

The senior vice president of research at Vaxxinity talked about research for a potential vaccine for migraine prevention presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided perspective on a phase 3 study of patients with NMOSD in which no relapses were recorded while on ravulizumab.

Nicholas Johnson, MD, MSci, FAAN, division chief of neuromuscular disorders and vice chair of research, Virginia Commonwealth University, provided insight on promising phase 1/2 data of AOC 1001 in myotonic dystrophy type 1.

The associate professor of neurology at Mayo Clinic Rochester discussed specific findings from a simultaneous comparison of migraine medications in which certain treatments and classes were more effective. [WATCH TIME: 3 minutes]

The assistant professor in the department of neurology at the Albert Einstein College of Medicine and Montefiore Medical Center talked about predictive models in Alzheimer disease for clinical trials. [WATCH TIME: 5 minutes]

Melanie Leitner, PhD, consultant and founder of Accelerating NeuroVentures, talked about the findings from regimen D of the HEALY ALS platform trial assessing pridopidine.

The director and chief research scientist at Tisch MS Research Center of New York talked about a phase 2 data study on stem cell treatment for multiple sclerosis that was presented at the 2023 AAN Annual Meeting. [WATCH TIME: 7 minutes]

Although it showed better functional outcomes, endovascular thrombectomy for the treatment of stroke because of basilar-artery occlusion was associated with procedural complications and intracerebral hemorrhage.

The director of the Mellen Center for MS at Cleveland Clinic talked about the ENSEMBLE study results that were presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Although the incidence of symptomatic intracranial hemorrhage was low, 18% of the patients in the endovascular thrombectomy group had complications associated with the procedure.

The assistant professor of neurology at Mayo Clinic spoke about understanding the phenotypes and epidemiology of autoimmune encephalitis at the 2023 AAN Annual Meeting. [WATCH TIME: 4 minutes]

In a subgroup of individuals with secondary progressive MS, 50% of patients on mesenchymal stem cell-neural progenitor therapy improved muscle strength compared with 33% of those on placebo.

The associate chief science officer at Kennedy Krieger Institute shared thoughts on the state of pediatric neurology and the significance of being named winner of the Sydney Carter Award. [WATCH TIME: 3 minutes]

The neurologist at Mayo Clinic in Jacksonville Florida provided perspective on his talk given at the 2023 AAN annual meeting on rapidly progressive dementia. [WATCH TIME: 6 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive interviews with Michael H. Barnett, MBBS, PhD, FRACP; Nancy R. Foldvary-Schaefer, DO, FAAN; Sean J. Pittock, MD; Katherine W. Turk, MD; Erika U. Augustine, MD, MS; Jeffrey M. Statland, MD; and Chian-Chun Chiang, MD. [LISTEN TIME: 41 minutes]

After 48 months of follow up, cipaglucosidase alfa/miglustat in cohorts of ambulatory patients with Pompe disease had an overall safety profile similar to the approved enzyme replacement therapy.

The associate professor of neurology at Mayo Clinic Rochester provided perspective on a new study presented at the 2023 AAN Annual Meeting assessing the treatment effectiveness of real-world patients with migraine. [WATCH TIME: 4 minutes]

Over 48 weeks of treatment, ALXN1480 was found to be generally well-tolerated, with improvements seen in Clinical Global Impression-Improvement scores and UWDRS Parts II and III.

The associate professor of neurology at Harvard Medical School talked about the subgroup analysis on ravulizumab in NMOSD that was presented at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

Presented at the 2023 AAN Annual Meeting, remote electrical neuromodulation demonstrated itself as an effective and safe treatment for the prevention of migraine when applied every other day.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, talked about a few of the studies on cenobamate for epilepsy presented at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

The neurologist at Montefiore Medical Center, Albert Einstein College of Medicine, discussed his experience in establishing a neurology department committee on diversity, equity, and inclusion. [WATCH TIME: 5 minutes]